Compare F5 Inc (FFIV) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Novo Nordisk A/S — how do they compare? F5 Inc trades at $421.52 (market cap $23.44B), while Novo Nordisk A/S trades at $46.25 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 8.9× F5 Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while F5 Inc pays none. Which is the better fit depends on your goals.
| FFIV | NVO | |
|---|---|---|
Market Cap | $23.44B | $207.85B |
Sector | Technology | Health |
52-Week High | $431.26 | $63.98 |
52-Week Low | $223.99 | $35.29 |
Enterprise Value | $22.08B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) stock trades at $417.70, up 1.88% with bullish technical signals and strong earnings beats. Recent Q3 2026 results showed EPS of $4.73 versus $4.00 expected, driven by 19% product revenue growth. The company raised its fiscal outlook, reflecting robust demand for application security and AI infrastructure. Key support lies at $411, with resistance at $422.
Outlook remains positive due to consistent earnings outperformance and raised guidance, though valuation multiples like P/E of 32.98 suggest premium pricing. Risks include competitive pressures and reliance on enterprise spending cycles. Analyst consensus price target of $430.43 implies moderate upside potential from current levels.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
